TCBP to Present at the 2024 ThinkEquity Conference in NYC
TC BioPharm, a clinical-stage biotechnology company developing allogeneic gamma-delta T cell therapies, announced its participation in the 2024 ThinkEquity Conference in New York City. CEO Bryan Kobel will present on October 30, 2024, at the Mandarin Oriental Hotel.
Kobel plans to discuss TC BioPharm's clinical trials and recent balance sheet improvements. The ThinkEquity Conference is a prominent event showcasing emerging growth companies from various sectors worldwide.
Interested parties can contact IR@tcbiopharm.com for more information or to schedule meetings with management. TC BioPharm trades on NASDAQ under the ticker TCBP.
TC BioPharm, una compagnia biotecnologica in fase clinica che sviluppa terapie con cellule T gamma-delta allogeniche, ha annunciato la sua partecipazione alla ThinkEquity Conference 2024 che si terrà a New York City. Il CEO Bryan Kobel presenterà il 30 ottobre 2024, presso il Mandarin Oriental Hotel.
Kobel prevede di discutere dei trials clinici di TC BioPharm e dei recenti miglioramenti del bilancio. La ThinkEquity Conference è un evento di rilievo che mette in mostra aziende emergenti in crescita da vari settori a livello mondiale.
Le parti interessate possono contattare IR@tcbiopharm.com per ulteriori informazioni o per pianificare incontri con la direzione. TC BioPharm è quotata su NASDAQ con il ticker TCBP.
TC BioPharm, una empresa de biotecnología en etapa clínica que desarrolla terapias con células T gamma-delta alogénicas, anunció su participación en la Conferencia ThinkEquity 2024 en la ciudad de Nueva York. El CEO Bryan Kobel presentará el 30 de octubre de 2024 en el Mandarin Oriental Hotel.
Kobel planea discutir los ensayos clínicos de TC BioPharm y las recientes mejoras en el balance general. La Conferencia ThinkEquity es un evento de renombre que exhibe empresas emergentes en crecimiento de diversos sectores a nivel mundial.
Las partes interesadas pueden contactar a IR@tcbiopharm.com para obtener más información o para programar reuniones con la dirección. TC BioPharm cotiza en NASDAQ bajo el símbolo TCBP.
TC BioPharm, 임상 단계의 생명공학 회사로서 동종의 감마 델타 T 세포 치료제를 개발하고 있으며, 2024 ThinkEquity Conference에 뉴욕시에서 참여한다고 발표했습니다. CEO Bryan Kobel은 2024년 10월 30일에 만다린 오리엔탈 호텔에서 발표할 예정입니다.
Kobel은 TC BioPharm의 임상 시험 및 최근의 재무상태 개선에 대해 논의할 계획입니다. ThinkEquity Conference는 전 세계 다양한 산업의 신흥 성장 기업을 소개하는 저명한 행사입니다.
관심 있는 분들은 IR@tcbiopharm.com으로 문의하거나 경영진과의 미팅을 예약할 수 있습니다. TC BioPharm은 NASDAQ에서 TCBP라는 티커로 거래됩니다.
TC BioPharm, une société de biotechnologie en phase clinique développant des thérapies à base de cellules T gamma-delta allogéniques, a annoncé sa participation à la ThinkEquity Conference 2024 qui se déroulera à New York. Le PDG Bryan Kobel fera une présentation le 30 octobre 2024 au Mandarin Oriental Hotel.
Kobel prévoit de discuter des essais cliniques de TC BioPharm et des récentes améliorations de la situation financière. La ThinkEquity Conference est un événement majeur qui met en avant des entreprises émergentes en croissance dans divers secteurs à travers le monde.
Les parties intéressées peuvent contacter IR@tcbiopharm.com pour plus d'informations ou pour planifier des réunions avec la direction. TC BioPharm est cotée sur le NASDAQ sous le symbole TCBP.
TC BioPharm, ein biopharmazeutisches Unternehmen in einer klinischen Phase, das allogene Gamma-Delta-T-Zelltherapien entwickelt, hat seine Teilnahme an der 2024 ThinkEquity Conference in New York City angekündigt. CEO Bryan Kobel wird am 30. Oktober 2024 im Mandarin Oriental Hotel präsentieren.
Kobel plant, über die klinischen Studien von TC BioPharm und die jüngsten Verbesserungen der Bilanz zu sprechen. Die ThinkEquity Conference ist eine bedeutende Veranstaltung, die aufstrebende Wachstumsunternehmen aus verschiedenen Branchen weltweit präsentiert.
Interessierte können IR@tcbiopharm.com kontaktieren, um weitere Informationen zu erhalten oder Meetings mit der Geschäftsleitung zu vereinbaren. TC BioPharm wird an der NASDAQ unter dem Tickersymbol TCBP gehandelt.
- None.
- None.
Mr. Kobel plans to provide insight into the company's clinical trials as well as recent improvements to TC BioPharm's balance sheet. For more information or to schedule a meeting with management, please contact; IR@tcbiopharm.com.
The ThinkEquity Conference is a premier showcase of private and public emerging growth companies from all over the world, this conference features presentations by public and private companies across many sectors.
About ThinkEquity
ThinkEquity is a boutique investment bank created by experienced professionals who have worked together for over a decade, collectively financing over
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T-cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue.
TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial in the treatment of acute myeloid leukemia using the Company's proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide.
View original content to download multimedia:https://www.prnewswire.com/news-releases/tcbp-to-present-at-the-2024-thinkequity-conference-in-nyc-302257052.html
SOURCE TC BioPharm
FAQ
When and where will TC BioPharm (TCBP) present at the ThinkEquity Conference?
What topics will TC BioPharm's CEO discuss at the 2024 ThinkEquity Conference?
How can investors schedule a meeting with TC BioPharm's management at the conference?
What type of therapies is TC BioPharm (TCBP) developing?
